JP2024502371A5 - - Google Patents
Info
- Publication number
- JP2024502371A5 JP2024502371A5 JP2023541864A JP2023541864A JP2024502371A5 JP 2024502371 A5 JP2024502371 A5 JP 2024502371A5 JP 2023541864 A JP2023541864 A JP 2023541864A JP 2023541864 A JP2023541864 A JP 2023541864A JP 2024502371 A5 JP2024502371 A5 JP 2024502371A5
- Authority
- JP
- Japan
- Prior art keywords
- binding protein
- bispecific epitope
- cancer
- bispecific
- epitope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163135812P | 2021-01-11 | 2021-01-11 | |
| US63/135,812 | 2021-01-11 | ||
| PCT/IB2022/000009 WO2022149050A2 (en) | 2021-01-11 | 2022-01-11 | Bispecific epitope binding protein comprising anti-4-1bb antibody and pd-1 protein or fragments thereof and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024502371A JP2024502371A (ja) | 2024-01-18 |
| JP2024502371A5 true JP2024502371A5 (enExample) | 2025-01-23 |
Family
ID=82357225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023541864A Pending JP2024502371A (ja) | 2021-01-11 | 2022-01-11 | 抗－４－１ｂｂ抗体およびｐｄ－１タンパク質またはその断片を含む二重特異的エピトープ結合タンパク質およびその用途 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12331116B2 (enExample) |
| EP (1) | EP4274852A4 (enExample) |
| JP (1) | JP2024502371A (enExample) |
| KR (2) | KR102618718B1 (enExample) |
| CN (1) | CN117321079A (enExample) |
| WO (1) | WO2022149050A2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022053864A1 (en) * | 2020-09-08 | 2022-03-17 | Kwon Byoung S | Pd-1 polypeptide variants |
| USD1094401S1 (en) * | 2023-02-20 | 2025-09-23 | Sony Interactive Entertainment Inc. | Display screen or portion thereof with transitional graphical user interface |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102178323B1 (ko) * | 2013-11-29 | 2020-11-13 | 삼성전자주식회사 | 항 c-Met/항 Ang2 이중 특이 항체 |
| US10899840B2 (en) * | 2014-02-04 | 2021-01-26 | Pfizer Inc. | Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer |
| KR102259232B1 (ko) * | 2014-08-25 | 2021-05-31 | 삼성전자주식회사 | 항 c-Met/항 Ang2 이중 특이 항체 |
| PE20231958A1 (es) * | 2015-07-30 | 2023-12-06 | Macrogenics Inc | Moleculas de union a pd-1 y metodos de uso de las mismas |
| WO2017070654A1 (en) * | 2015-10-23 | 2017-04-27 | Sorrento Therapeutics, Inc. | Programmable universal cell receptors and methods of using the same |
| WO2017123548A1 (en) * | 2016-01-14 | 2017-07-20 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Tumor-specific ifna secretion by car t-cells to reprogram the solid tumor microenvironment |
| US11365237B2 (en) * | 2016-03-23 | 2022-06-21 | Helmholtz Zentrum Muenchen—Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) | Fusion proteins of PD-1 and 4-1BB |
| JP7125400B2 (ja) * | 2016-12-19 | 2022-08-24 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 標的化４－１ｂｂ（ｃｄ１３７）アゴニストとの併用療法 |
| CA3047070A1 (en) * | 2017-01-03 | 2018-07-12 | F.Hoffmann-La Roche Ag | Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9 |
| US10174122B2 (en) * | 2017-01-06 | 2019-01-08 | Eutilex Co., Ltd. | Anti-human 4-1BB antibodies and uses thereof |
| JP2020522495A (ja) * | 2017-05-30 | 2020-07-30 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物 |
| KR20250020679A (ko) * | 2017-08-04 | 2025-02-11 | 젠맵 에이/에스 | Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도 |
| US11718679B2 (en) * | 2017-10-31 | 2023-08-08 | Compass Therapeutics Llc | CD137 antibodies and PD-1 antagonists and uses thereof |
| KR20240017090A (ko) * | 2018-03-23 | 2024-02-06 | 일라이 릴리 앤드 캄파니 | 항-pd-1 항체와의 조합을 위한 항-cd137 항체 |
| WO2019241758A1 (en) * | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
| EP3823988A1 (en) * | 2018-07-19 | 2021-05-26 | Eli Lilly and Company | Bispecific antibodies targeting immune checkpoints |
| MX2021002292A (es) * | 2018-08-29 | 2021-05-27 | Shattuck Labs Inc | Terapias de combinacion que comprenden proteinas quimericas basadas en sirp alfa. |
| KR20210058902A (ko) * | 2018-09-14 | 2021-05-24 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | sPD-1 변이체-FC 융합 단백질 |
| WO2020068500A1 (en) * | 2018-09-26 | 2020-04-02 | Albert Einstein College Of Medicine | Mutant variants of pd-1 receptor with selective binding to pd-l1 and uses thereof |
| GB201817822D0 (en) * | 2018-10-31 | 2018-12-19 | Autolus Ltd | Binding domain |
| SG11202105152YA (en) * | 2018-11-30 | 2021-06-29 | Abl Bio Inc | Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof |
| US20220220215A1 (en) * | 2019-05-15 | 2022-07-14 | Crescendo Biologics Limited | Binding molecules |
| WO2021007428A2 (en) * | 2019-07-09 | 2021-01-14 | The Johns Hopkins University | Molecules, compositions and methods for treatment of cancer |
| CN112646031B (zh) * | 2019-10-10 | 2021-12-07 | 天境生物科技(上海)有限公司 | 抗4-1bb纳米抗体及其用途 |
| CN110669137B (zh) * | 2019-10-24 | 2021-07-16 | 高新 | 一种多特异性抗体及其制备方法和用途 |
| WO2022053864A1 (en) * | 2020-09-08 | 2022-03-17 | Kwon Byoung S | Pd-1 polypeptide variants |
-
2022
- 2022-01-11 CN CN202280009724.5A patent/CN117321079A/zh active Pending
- 2022-01-11 US US17/647,665 patent/US12331116B2/en active Active
- 2022-01-11 WO PCT/IB2022/000009 patent/WO2022149050A2/en not_active Ceased
- 2022-01-11 KR KR1020227040417A patent/KR102618718B1/ko active Active
- 2022-01-11 EP EP22736677.0A patent/EP4274852A4/en active Pending
- 2022-01-11 KR KR1020237005801A patent/KR102576861B1/ko active Active
- 2022-01-11 JP JP2023541864A patent/JP2024502371A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022064924A5 (enExample) | ||
| JP2022065174A5 (enExample) | ||
| JP2025163055A5 (enExample) | ||
| Zuo et al. | An efficient route to the production of an IgG-like bispecific antibody | |
| Fernández | Prokaryotic expression of antibodies and affibodies | |
| RU2015144098A (ru) | Четырехвалентные биспецифические антитела | |
| US20100158925A1 (en) | Lyophilized formulations of anti-egfr antibodies | |
| RU2015122484A (ru) | Агенты для лечения экспрессирующих клаудин раковых заболеваний | |
| JP2020195399A5 (enExample) | ||
| CN105194661A (zh) | 时空可调性抑制病理性靶细胞的系统 | |
| ES3037145T3 (en) | Antigen binding protein against her3 | |
| JP2023539501A5 (enExample) | ||
| JP2014113150A5 (enExample) | ||
| JP2024116283A5 (enExample) | ||
| JP2017503480A5 (enExample) | ||
| RU2022102446A (ru) | Биспецифические связывающие белки и пути их применения | |
| WO2003046560B1 (en) | Self-assembly molecules | |
| JP2021525537A5 (enExample) | ||
| JP2024527020A5 (enExample) | ||
| Leenheer et al. | A current perspective on applications of macrocyclic‐peptide‐based high‐affinity ligands | |
| JP2025503731A5 (enExample) | ||
| CA3142735A1 (en) | Antigen-binding protein constructs and uses thereof | |
| CN114522244B (zh) | 视黄酸修饰的lytac分子及其制备方法和应用 | |
| JP2022524753A5 (enExample) | ||
| CA1297049C (en) | Monoclonal antibodies against activated ras proteins with amino acid mutations at position 13 of the protein |